Action,ActionId,AuthorityGroup,Company,CompanyId,CompanyOwnershipRelationship,Country,CountryId,Drug,DrugId,DrugRelationship,EntityType,HighestPatStatus,HighestPatStatusForCnty,HighestPatStatusId,HighestPatStatusIdForCnty,Indication,IndicationId,LatestChange,ParentCompany,ParentCompanyId,Patent,PatentId,Status,StatusDate,StatusId,StatusSortCode,TherapyArea,TherapyAreaId
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Neoplasm,230
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Infectious disease,746
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,World,WO,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Publication,2012-11-29 00:00:00,PUB,2,Endocrine disease,112
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,urelumab,23886,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,World,WO,palivizumab,8747,General interest,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF ligand inhibitor,12521,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Insulin-like growth factor 1 receptor antagonist,3252,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF1 receptor antagonist,3682,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
FGF2 receptor antagonist,3685,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
VEGF-1 receptor antagonist,3846,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
CD3 antagonist,5025,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 inhibitor,5082,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
TNF antagonist,511,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Hepatocyte growth factor receptor antagonist,675,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Inflammatory disease,188
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Dermatological disease,95
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Neoplasm,230
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Infectious disease,746
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Immune disorder,185
Epidermal growth factor receptor antagonist,740,null,Zyngenia Inc,1050617,Owner,US,US,"tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia",77135,General interest,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Zyngenia Inc,1050617,WO-2012162561,PA7191557,First Priority,2011-05-24 00:00:00,PRI,1,Endocrine disease,112
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
CDw123 antagonist,5429,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164305,PA8994513,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,urelumab,23886,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Rare disease,9099
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Hematological disease,142
T-lymphocyte stimulator,7761,null,Zyngenia Inc,1050617,Third Party,US,US,palivizumab,8747,General interest,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Zyngenia Inc,1050617,WO-2016164308,PA8994514,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,World,WO,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Publication,2012-01-19 00:00:00,PUB,2,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia",71794,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Angiopoietin ligand-2 inhibitor,14323,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Inflammatory disease,188
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Neoplasm,230
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Immune disorder,185
TNF alpha ligand inhibitor,381,null,Zyngenia Inc,1050617,Owner,US,US,"anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia",71795,Product,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Zyngenia Inc,1050617,WO-2012009705,PA6726805,First Priority,2010-07-15 00:00:00,PRI,1,Gastrointestinal disease,129
ApoB editing catalytic polypeptide stimulator,14770,null,Zyngenia Inc,1050617,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Genetic disorder,609,null,Zyngenia Inc,1050617,WO-2010132092,PA6253839,First Publication,2010-11-18 00:00:00,PUB,2,Genetic disorder,609
Cytidine deaminase stimulator,7118,null,Zyngenia Inc,1050617,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Genetic disorder,609,null,Zyngenia Inc,1050617,WO-2010132092,PA6253839,First Publication,2010-11-18 00:00:00,PUB,2,Genetic disorder,609
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Infectious disease,746
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Infectious disease,746
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Infectious disease,746
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Infectious disease,746
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Immune disorder,185
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Publication,2012-08-16 00:00:00,PUB,2,Infectious disease,746
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Immune disorder,185
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Infectious disease,746
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Immune disorder,185
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Infectious disease,746
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Immune disorder,185
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Infectious disease,746
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Immune disorder,185
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Infectious disease,746
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Immune disorder,185
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Infectious disease,746
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Immune disorder,185
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Infectious disease,746
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Hematological disease,142
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Immune disorder,185
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Publication,2014-02-20 00:00:00,PUB,2,Infectious disease,746
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164369,PA8994530,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164369,PA8994530,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164369,PA8994530,First Publication,2016-10-13 00:00:00,PUB,2,Neoplasm,230
ApoB editing catalytic polypeptide stimulator,14770,null,Zyngenia Inc,1050617,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Genetic disorder,609,null,Zyngenia Inc,1050617,WO-2010132092,PA6253839,First Priority,2009-05-12 00:00:00,PRI,1,Genetic disorder,609
Cytidine deaminase stimulator,7118,null,Zyngenia Inc,1050617,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Genetic disorder,609,null,Zyngenia Inc,1050617,WO-2010132092,PA6253839,First Priority,2009-05-12 00:00:00,PRI,1,Genetic disorder,609
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Neoplasm,230
Interleukin-1 beta ligand inhibitor,12479,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Infectious disease,746
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Neoplasm,230
MIP-3 beta ligand inhibitor,17067,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Infectious disease,746
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Neoplasm,230
VEGF receptor antagonist,1722,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Infectious disease,746
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Neoplasm,230
CCR5 chemokine antagonist,3107,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Infectious disease,746
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Neoplasm,230
Erbb2 tyrosine kinase receptor inhibitor,3756,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Neoplasm,230
B-lymphocyte antigen CD20 inhibitor,5085,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Infectious disease,746
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Immune disorder,185
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Neoplasm,230
Transferrin receptor protein antagonist,75286,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2012109624,PA7057914,First Priority,2011-02-11 00:00:00,PRI,1,Infectious disease,746
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Immune disorder,185
Factor I modulator,1320,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Infectious disease,746
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Immune disorder,185
Transferrin modulator,1515,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Infectious disease,746
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Immune disorder,185
CD3 modulator,5023,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Infectious disease,746
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Immune disorder,185
B-lymphocyte antigen CD19 modulator,5080,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Infectious disease,746
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Immune disorder,185
Thyroxine binding globulin modulator,51332,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Infectious disease,746
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Immune disorder,185
ELP gene stimulator,69528,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Infectious disease,746
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Hematological disease,142
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Immune disorder,185
Albumin modulator,815,null,Zyngenia Inc,1050617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Zyngenia Inc,1050617,WO-2014028776,PA7670275,First Priority,2012-08-15 00:00:00,PRI,1,Infectious disease,746
Programmed cell death ligand 1 inhibitor,14007,null,Zyngenia Inc,1050617,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164369,PA8994530,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
CDw137 antagonist,5451,null,Zyngenia Inc,1050617,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164369,PA8994530,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230
Neoplasm diagnostic agent,7220,null,Zyngenia Inc,1050617,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Zyngenia Inc,1050617,WO-2016164369,PA8994530,First Priority,2015-04-06 00:00:00,PRI,1,Neoplasm,230